FDA Wants Cardiovascular Safety Data Before Approving Insulin Degludec

The FDA informed Novo Nordisk on Friday that it would not approve the company's highly anticipated long-acting insulin degludec products (Tresiba and ...

To continue reading, please log in to the right or request an invitation.